The Hemophilia Center is currently conducting or participating in over 25 active clinical research protocols. These include industry-sponsored new drug trials, and well as NIH and privately-funded multi-center clinical and epidemiologic studies on which Drs. DiMichele or Acharya are principal investigators.

Our center has several approaches to long-term hemophilia care available to our patients who wish to participate. We embrace the opportunity to educate the bleeding disorders community about the latest treatment plans that have proven to be beneficial and allow for a healthy and productive livelihood. Patients that are followed at our treatment center who meet eligibility criteria for research protocols are offered the opportunity to enroll if they choose to do so.

• A Randomized Prospective Study for the Prevention of Joint Disease in Children with Factor VIII Deficiency
• An International, Randomized, Controlled Trial of Immune Tolerance Induction
• Universal Data and Serum Specimen Collection System for Hemophiliacs
• Comprehensive Care in Patients with Hemophilia
• Epidemiology and Immunology of Hemophilia A Inhibitors
• Fibrogammin P: Human Plasma Derived FXIII Concentrate in patients with Congenital FXIII Deficiency
• Genetics of Inhibitor Formation in Hemophilia
• Second Multicenter Hemophilia Cohort Study
• The Anonymous Use of Waste Blood Samples for Disease-Related Research
• The FEIBA NovoSeven Comparative Study (The FENOC Study)
• Therapeutic Plasmapheresis with Excorim Immunoadsorption System
• Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated without Added Human or Animal Proteins: Evaluation of Pharmokinetics, Safety, Efficacy and Immunogenicity in Previously Treated Severe Hemophilia A Patients
• Evaluation of Pharmacokinetics, Safety, Efficacy and Immunogenicity of rAHF-PFM in Previously Treated Hemophilia A Patients - A Continuation Study
• Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated without Added Human or Animal Proteins: Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures
• A Single-Dose Randomized, Double-Blind, 2-Period Crossover Study in Patients with Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)
• A Single-Dose Randomized, Double-Blind, 2-Period Crossover Study in Patients with Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)
• An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) with Severe Hemophilia A
• An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) with Severe Hemophilia A
• Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Pharmacokinetics, Immunogenicity, Efficacy and Safety in Previously Treated Pediatric Patients with Hemophilia A
• The Use of a Computational Model as a Predictor of Bleeding in Severe Hemophilia A
• Retrospective Comparison Between Daily and Alternate Day Immune Tolerance Regimens in Severe Hemophilia A.
• Plasma and Platelet Factor V and VII Activity in Apheresis Single Donor Platelet Concentrates Stored Up to 7 Days.
• The Utility of Waveform Analysis in the Diagnosis and Management of Hemophilia A and Hemophilia B.
• National Registry for Rare Bleeding Disorders